Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.67 |
-0.62 |
0.05 |
7.46% |
2024-02-27 |
2023-12 |
-0.78 |
-0.79 |
-0.01 |
-1.28% |
2024-02-27 |
2023-12 |
-0.78 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.85 |
-0.92 |
-0.07 |
-8.24% |
2023-11-09 |
2023-09 |
-0.85 |
N/A |
N/A |
N/A |
2023-08-10 |
2023-06 |
-0.71 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-09 |
Stifel |
Upgrade |
Buy |
Buy |
2023-10-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-28 |
Morgan Stanley |
Upgrade |
Overweight |
Overweight |
2023-08-10 |
Credit Suisse |
Upgrade |
Outperform |
Outperform |
2023-08-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-04 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-04-01 |
AUSTER MARTIN |
Chief Financial Officer |
24.30K |
Sale |
2023-03-29 |
GUJRATHI SHEILA |
Director |
0.00 |
Sale |
2024-04-01 |
KRUEGER CHRISTOPHER W |
Officer |
285.00K |
Sale |
2024-04-01 |
MOHAN RAJU |
Chief Executive Officer |
1.58M |
Sale |
2022-11-06 |
NSV INVESTMENTS I, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2023-10-08 |
NSV PARTNERS III LP |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
FMR, LLC |
8.55M |
280.55M |
14.57% |
2023-06-29 |
Price (T.Rowe) Associates Inc |
3.95M |
129.54M |
6.73% |
2023-06-29 |
Blackrock Inc. |
3.23M |
105.83M |
5.50% |
2023-06-29 |
Citadel Advisors Llc |
2.79M |
91.42M |
4.75% |
2023-06-29 |
Capital International Investors |
2.73M |
89.47M |
4.65% |
2023-06-29 |
Vanguard Group Inc |
2.38M |
78.22M |
4.06% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Smallcap World Fund |
2.73M |
89.47M |
4.65% |
2023-06-29 |
Price (T.Rowe) New Horizons Fund |
1.65M |
54.06M |
2.81% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.42M |
46.51M |
2.42% |
2023-07-30 |
Lord Abbett Developing Growth Fund |
1.23M |
45.73M |
2.10% |
2023-08-30 |
iShares Russell 2000 ETF |
1.07M |
35.81M |
1.82% |
2023-07-30 |
Fidelity Advisor Biotechnology Fund |
1.01M |
37.32M |
1.72% |